Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill
Published 3 months, 1 week ago
Description
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.